Japan has approved AstraZeneca’s Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
Related Keywords
Japan , Japanese , Naoki Kashihara , Astrazeneca Forxiga , Japanese Society Of Nephrology , Japanese Ministry Of Health , Japanese Ministry , Ono Pharmaceutical ,
comparemela.com © 2020. All Rights Reserved.